Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study

April 19 (Bloomberg) -- Bristol-Myers Squibb Co. said its experimental hepatitis C compounds, protease inhibitor asunaprevir combined with its NS5A inhibitor daclatasvir, cured 77 percent of difficult-to-treat patients 24 weeks after treatment ended, according to a mid-stage study.

Difficult-to-treat patients included those who didn’t respond to prior therapy and patients who were medically ineligible or intolerant to previous treatment, the company said in a statement today.

In a separate mid-stage study, Bristol-Myers’ experimental peginterferon lambda drug had a cure rate similar to peginterferon alfa with fewer side effects, the company said.

To contact the reporter on this story: Makiko Kitamura in London at mkitamura1@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.